Oncolytics Biotech is trading at $0.53, down -5.55%, with the decline unexplained.
- No reliable report ties the October 12 decline to a specific company catalyst.
- REO 033 enrollment progress appears to be earlier news, not a confirmed explanation for this move.
- Major indexes were nearly flat, and available evidence does not establish a cause.